Eravacycline – Injection Products

FDA-Identified Interpretive Criteria

	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion (zone diameter in mm)
Pathogen	S	I	R	S	I	R
Enterobacteriaceaea	≤0.5	-	-	≥15	-	-
Staphylococcus aureus	≤0.06	-	-	-	-	-
Enterococcus faecalis and Enterococcus faecium	≤0.06	-	-	-	-	-
Streptococcus anginosus groupb	≤0.06	-	-	-	-	-
Anaerobesc	≤0.5	-	-	-	-	-

S=Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 20 mcg eravacycline

^a Clinical efficacy was shown for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumonia.
^b Clinical efficacy was shown for S. anginosus, S. constellatus, S. intermedius.
^c Clinical efficacy was shown for Clostridium perfringens, Parabacteroides distasonis, Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus.